# A Field Guide to Medical Communications, 2026–2030 > A scenario map of the AI era in medical communications — the factions (sponsor-side automation, writer-side co-creation, agencies, freelancers, reviewers), the terrain they fight on, and how the tug-of-war plausibly unfolds. A forecast, clearly labeled as one. > This is a map of a war that has already started, drawn by a participant. Treat it accordingly: it is Mantir's forecast — scenario, not reportage — anchored to real events where they exist and honest speculation where they don't. The war is over a single question: **when AI enters medical communications, does it replace the writer or arm the writer?** Every faction below is an answer to that question with a budget attached. ## The factions **The Sponsors (pharma commercial & procurement).** Command the money and feel the squeeze — pipelines demand more materials, agencies bill by the deliverable, and every earnings call rewards an "AI efficiency" story. Their move: buy [one-button authoring](/perspectives/one-button-authoring/) and bet the agency line item shrinks. Real signal: strategic pharma money is already inside the tooling — Eli Lilly participated in Revisto's November 2024 seed round. Their weakness: they buy at portfolio distance from the work, so they systematically underprice the [substantiation gap](/perspectives/substantiation-gap/). **The Button-Makers (sponsor-side AI vendors).** Well-funded, fluent, demo-beautiful. Their pitch is speed: "90% faster" (vendor claims all, unaudited). Their products genuinely compress the typing. Their existential problem: everything they generate still has to cross the [MLR wall](/perspectives/the-mlr-wall/), and a wall doesn't care how fast you approached it. **The Guilds (medcomms agencies).** Scientific, editorial, and client-services pillars; decades of accumulated judgment about what survives review and what a client meant by that email. Under visible [agency compression](/perspectives/agency-compression/) — sponsors asking why the deck costs what it costs. Their fork in the road: adopt [writer-side AI](/perspectives/writer-side-ai/) and sell judgment-at-machine-speed, or race the buttons on price and lose. **The Free Companies (freelance medical writers).** The most exposed and the most agile — no procurement department, no validated stack, free to adopt any tool tomorrow. (Median rate per Upwork's own data: $36/hour; specialists far above it.) In every prior automation wave, independents who armed themselves early captured outsized share as buyers learned the difference between generated and *good*. **The Wardens (MLR committees, final medical signatories, OPDP/PMCPA).** The terrain-owners. They don't compete in the market; they *are* the ground it's fought on. Their incentives are asymmetric — a reviewer gets no credit for approving fast and full blame for approving wrong — which makes them structurally immune to fluency and obsessed with provenance. Nothing about generative AI changes their incentives; it only changes the volume of unverified content arriving at their gate. **The Armorers (writer-side toolmakers — where Mantir stands).** Build for the writer instead of over them: evidence-linked authoring, live substantiation, pre-review agents. The bet: in a regulated industry, the tool that owns *verification* outlasts the tool that owns generation — the [verification asymmetry](/perspectives/verification-asymmetry/) guarantees the bottleneck lands there. ## The terrain Three features of the battlefield decide more than any tool's model quality: 1. **The MLR wall.** Every deliverable crosses it; nothing ships around it. Content that arrives substantiated crosses in one round; content that arrives fluent-but-unverified queues, bounces, and re-queues. The wall converts "generated fast" into "parked longer." 2. **The provenance ledger.** Claims, evidence, versions, annotations. Whoever maintains it — spreadsheet, vault, or writer-side library — holds the industry's actual source of truth. Buttons don't want to keep ledgers; ledgers are where their outputs get falsified. 3. **The trust gradient.** Reviewers extend goodwill to writers whose packs verify cleanly, and goodwill is measured in rounds. It accrues to *people*, not tools — which is why tools that make their humans look immaculate compound, and tools that make humans into rubber stamps ([human-as-the-loop](/perspectives/human-as-the-loop/)) burn the gradient down. ## How it plausibly unfolds **2026 — The demo years (now).** Buttons proliferate; pilots everywhere; slideware victories. Early writer-side tools reach working writers. Review queues quietly lengthen where generated volume rises. *You are here.* **2027 — The wall bill arrives.** The first honest post-mortems: generated deliverables didn't reduce total cycle time, they moved the cost from writing to review. Findings-per-submission becomes a tracked metric. Sponsors start asking vendors the awkward question: *show me rounds, not drafts.* **2028 — The great re-sort.** Procurement splits the category it once lumped: generation tools (cheap, commoditizing) versus verification tools (sticky, workflow-owning). Agencies that armed their writers publish cycle-time numbers agencies that didn't can't match. Freelancers with substantiation tooling win work that used to require an agency's back office. **2029 — Judgment premium.** The market reprices what it's actually short of: accountable judgment. Signatory and reviewer capacity — never automatable, structurally scarce — sets the industry's clock speed. Tools are evaluated by one number: verified-claims-per-reviewer-hour. **2030 — The settlement.** Nobody's flag in the mud. Buttons survive as drafting utilities inside co-creation workflows — demoted from "replaces the writer" to "types the boring parts." The writer survives promoted: fewer, better-armed, owning the ledger and the judgment. The agencies that survive look less like deliverable factories and more like judgment houses with very good armories. ## What would falsify this map Forecasts you can't lose are propaganda, so: this map is wrong if regulators materially relax substantiation requirements (the wall shortens); if models learn to verify against sources as reliably as they generate (the asymmetry closes from the other side); or if sponsors prove willing to absorb regulatory risk at scale for speed (the trust gradient stops mattering). We watch all three. So should you. --- Source: https://medcom.claims/perspectives/field-guide-2030/ · Updated 2026-07-13 · © Mantir, Inc.